Lexaria Bioscience Corp. (NASDAQ: LEXX) reached a myriad of milestones in 2021, with CEO Chris Bunka noting in an annual letter to shareholders that January 2021 marked the birth of a modern version of the company. A recent article contains excerpts from the letter, in which Bunka writes: “In 2021, we completed research and development (“R&D”) and validated work equal to or greater than the entire combined amount previously achieved since 2018! We have conducted studies in broad areas of interest, but we have also focused on specific areas for which we have supporting data. and heart disease. And starting in April or possibly earlier, the company plans to begin dosing in its largest-ever hypertension study. Prior to this spring, Lexaria also plans to initiate a complex animal study evaluating DehydraTECH-CBD as a potential treatment to inhibit seizure activity. The Company will also continue efficacy modeling through 2022 with DehydraTECH-CBD in animals for other possible therapeutic indications, in addition to initiating a human study evaluating the ability of DehydraTECH to promote nicotine delivery characteristics. in oral tissues. “The goal of our three major studies is to generate enough data to support regulated IND-type applications or to drive corporate partnerships within their appropriate market sectors. We are optimistic about the positive results – noting that the science can be unpredictable – and, if so, we expect 2022 to be our most exciting year ever!”
To see the full article, visit https://cnw.fm/ilmjC
About Lexaria Bioscience Corp.
Lexaria’s patented drug delivery technology, DehydraTECH(TM), improves the way active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting more efficient oral delivery. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption with cannabinoids and nicotine by 5-10 times and in some cases with cannabinoids up to 27 times compared to standard formulations of the industry, reduce onset time from one to two hours to minutes and masks unwanted tastes. The technology is also being evaluated for oral antiviral drugs, nonsteroidal anti-inflammatory drugs (“NSAIDs”), PDE5 inhibitors, and more. DehydraTECH has also demonstrated the ability to deliver certain drugs more efficiently across the blood-brain barrier. Lexaria operates an in-house licensed research laboratory and holds a strong intellectual property portfolio with 23 granted patents and more than 50 patents pending worldwide. For more information, visit the company’s website at www.LexariaBioscience.com.
NOTICE TO INVESTORS: The latest LEXX news and updates are available from the company’s newsroom at https://cnw.fm/LEXX
CannabisNewsWire (CNW) is a news service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize company news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full range of corporate communications solutions. As a multi-faceted financial news and content distribution company with an extensive team of reporters and editors, CNW is uniquely positioned to better serve private and public companies seeking to reach a wide audience of investors. , consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 major syndication outlets across the country. By reducing the information overload in today’s marketplace, CNW provides its clients with unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.
To receive SMS alerts from CannabisNewsWire, text “CANNABIS” to 21000 (US cell phones only)
For more information, please visit https://www.CannabisNewsWire.com
Do you have questions or are you interested in working with CNW? Ask our editor
CannabisNewsWire is part of the InvestorBrandNetwork.